Psoriasis Drugs Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies), By Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, Others), By Route of Administration (Oral, Parenteral, Topical), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 22.36 Billion
CAGR (2026-2031)	6.69%
Fastest Growing Segment	Oral
Largest Market	North America
Market Size (2031)	USD 32.98 Billion

Market Overview

The Global Psoriasis Drugs Market is projected to grow from USD 22.36 Billion in 2025 to USD 32.98 Billion by 2031 at a 6.69% CAGR. Psoriasis drugs comprise pharmaceutical agents specifically developed for the treatment of psoriasis, a chronic autoimmune inflammatory skin condition. The market's growth is primarily supported by the increasing global prevalence of the disease, coupled with continuous advancements in targeted biological and novel small-molecule therapies that offer improved efficacy and patient outcomes. Furthermore, rising awareness and enhanced diagnostic capabilities contribute to an expanding patient pool seeking effective treatments. According to the International Federation of Psoriasis Associations (IFPA) in its Global Psoriasis Atlas (Third Edition) released in 2025, an estimated 43 million individuals worldwide have received a physician or dermatologist diagnosis for psoriasis.

Despite these growth drivers, a significant challenge impeding market expansion is the substantial cost associated with advanced biological treatments. These high expenditures can lead to considerable access barriers for patients and healthcare systems globally, potentially limiting broader adoption and market penetration, especially in regions with constrained healthcare budgets.

Key Market Drivers

The increasing global prevalence of psoriasis significantly drives the expansion of the psoriasis drugs market, as a larger patient population necessitates effective treatment solutions. This growing disease burden fuels demand for both existing and novel therapeutic agents. For instance, according to HCPLive in November 2025, a global analysis indicated that the age-standardized incidence rate for male psoriasis patients rose by 10.3% between 1990 and 2021, underscoring a continuous upward trend in new cases. This persistent rise in incidence and overall patient numbers creates a sustained need for pharmaceutical interventions, ranging from topical applications to advanced systemic treatments, thereby underpinning market growth.

Concurrently, continuous advancements in biologic and targeted therapies are profoundly influencing the market by offering superior efficacy and improved patient outcomes. These innovations address previously unmet needs and expand the therapeutic landscape. For example, according to the National Psoriasis Foundation in December 2025, new long-term data for the TYK2 inhibitor deucravacitinib demonstrated that 70% of patients maintained a Psoriasis Area Severity Index score of 75 over five years, indicating sustained therapeutic benefits. This pursuit of advanced treatments and their successful market introduction contributes substantially to the overall valuation of the market. According to Fierce Pharma in October 2025, Skyrizi, a prominent biologic in the psoriasis space, achieved sales of $4.7 billion in the third quarter of 2025, marking a substantial 47% year-over-year increase. This robust performance of leading drugs highlights the commercial impact of therapeutic innovation.

Download Free Sample Report

Key Market Challenges

The challenging factor impeding the growth of the Global Psoriasis Drugs Market is the substantial cost associated with advanced biological treatments. These high expenditures represent a significant barrier to market expansion, directly limiting broader patient access and market penetration, particularly in regions with constrained healthcare budgets. The considerable financial burden often prevents patients and healthcare systems from adopting these highly effective therapies, despite their improved efficacy and patient outcomes.

The elevated cost of biologics leads to significant access challenges. For instance, a retrospective cohort study published in December 2025 in Clinical Dermatology reported that barriers to initiating biologic treatments were encountered by 15.5% of patients, primarily due to insurance denials or lapses. This directly impacts market growth by reducing the uptake of advanced drugs, as affordability concerns often outweigh the clinical benefits for many potential patients globally. The necessity for long-term treatment further amplifies the financial strain, contributing to treatment discontinuation or non-initiation, thus hindering overall market volume and revenue generation.

Key Market Trends

The emergence of novel oral small molecule therapies is significantly reshaping the global psoriasis drugs market by offering patients more convenient treatment options compared to traditional injectables. This shift addresses a crucial need for less invasive administration routes, potentially improving patient adherence and overall treatment experience. These therapies provide a distinct advantage for individuals seeking effective systemic treatment without the burden of injections, thereby expanding the eligible patient pool and influencing prescribing patterns. For example, Bristol Myers Squibb is set to offer its oral TYK2 inhibitor, deucravacitinib (Sotyktu), through its BMS Patient Connect platform starting January 2026, where eligible patients can purchase it for $950 per month, representing approximately an 86% discount from its list price. This pricing strategy further enhances accessibility and drives the adoption of such innovative oral treatments.

Concurrently, the expanding adoption of biosimilar drugs is a pivotal trend, particularly in mitigating the high costs associated with advanced biological treatments. Biosimilars introduce competition, which drives down prices and enhances affordability, allowing broader patient access to effective therapies that were previously economically prohibitive for many. This increased access is critical for healthcare systems globally striving to manage budgets while improving patient outcomes. According to a study funded by Sandoz, published April 10, 2025, in a FirstWord Pharma press release titled 'IMKASID 2025: Study Shows Ustekinumab Biosimilars Could Save €526 Million Across European Markets', total expected savings from ustekinumab biosimilars were estimated to be €526 million in Germany, the United Kingdom, and Sweden over three years. The introduction of these cost-effective alternatives is fostering a more competitive market landscape and enabling greater treatment penetration.

Segmental Insights

The Oral segment is rapidly emerging as the fastest-growing sector within the Global Psoriasis Drugs Market, primarily driven by evolving patient and physician preferences for convenient and less invasive treatment options. The introduction of innovative, highly effective oral therapies, such as first-in-class targeted oral peptides, offers comparable efficacy to some injectable biologics, while also presenting favorable safety profiles. This has been further accelerated by proactive regulatory approvals from bodies like the U.S. Food and Drug Administration (FDA) for breakthrough oral medications. Consequently, these advancements are influencing an earlier adoption of systemic therapy for a broader patient population, aligning with guidance from institutions such as the International Psoriasis Council.

Regional Insights

North America dominates the global psoriasis drugs market, primarily driven by its advanced healthcare infrastructure and the high prevalence of psoriasis across the region. This robust foundation supports extensive research and development initiatives by major pharmaceutical companies, fostering continuous innovation in treatment options. The widespread adoption of advanced biologic and targeted therapies is further facilitated by strong insurance coverage and favorable reimbursement policies, making these often costly treatments accessible to a larger patient population. Additionally, efficient regulatory processes, exemplified by approvals from bodies such as the U.S. Food and Drug Administration, accelerate the market entry of novel drugs.

Recent Developments

• In March 2026, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide designed to precisely block the IL-23 receptor, offering a unique oral treatment option for patients.
• In February 2026, Eli Lilly and Company announced positive topline results from the TOGETHER-PsO open-label Phase 3b clinical trial, evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) for adults with moderate-to-severe plaque psoriasis and obesity or overweight. The study met its primary and all key secondary endpoints at 36 weeks, demonstrating superior skin clearance and weight loss compared to Taltz monotherapy. This combination therapy offers a potential advancement for psoriasis patients with comorbidities, addressing a significant unmet need within the global psoriasis drugs market.
• In December 2025, Takeda Pharmaceutical announced positive topline results from two pivotal Phase III clinical trials for zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, for adults with moderate-to-severe plaque psoriasis. The Latitude studies demonstrated zasocitinib's superiority over placebo for key endpoints, including static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at the 16-week mark. This breakthrough research provides new data supporting the efficacy of an oral treatment option in the global psoriasis drugs market.
• In September 2025, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved TREMFYA® (guselkumab) for the treatment of children aged six years and older, weighing at least 40 kg, with moderate-to-severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis. This approval marks TREMFYA® as the first and only IL-23 inhibitor to receive such pediatric indications, building upon its existing adult approvals for moderate-to-severe plaque psoriasis and active psoriatic arthritis. The National Psoriasis Foundation expressed support for new treatment options to alleviate the pain, discomfort, and emotional burden associated with these conditions.

Key Market Players

• AbbVie Inc.
• Johnson & Johnson
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• UCB S.A.
• Bristol Myers Squibb Company
• Sun Pharmaceutical Industries Ltd.
• Almirall, S.A.
• Boehringer Ingelheim International GmbH

By Type of Treatment	By Mechanism of Action	By Route of Administration	By Region
Biologic Drugs Small Molecule Systemic Drugs Tropical Therapies	TNF Alpha Inhibitors PDE4 Inhibitors Interleukin Inhibitors Others	Oral Parenteral Topical	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Psoriasis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Psoriasis Drugs Market, By Type of Treatment:

• Biologic Drugs
• Small Molecule Systemic Drugs
• Tropical Therapies

• Psoriasis Drugs Market, By Mechanism of Action:

• TNF Alpha Inhibitors
• PDE4 Inhibitors
• Interleukin Inhibitors
• Others

• Psoriasis Drugs Market, By Route of Administration:

• Oral
• Parenteral
• Topical

• Psoriasis Drugs Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE